Oncology

Latest News

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

July 15th 2025

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Insurance gaps | Image Credit: iQoncept-stock.adobe.com
Insurance Gaps Threaten Cancer Treatment Success

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

FDA approval. | Image Credit: syahrir - stock.adobe.com
November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro
Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.
Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com
November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser
Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).
Kasey Bond, MPH, Perlmutter Cancer Center
November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Maggie L. Shaw
Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
FDA Approval-BHM-stock.adobe.com
November 14th 2024

FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions

Giuliana Grossi
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Oscar B. Lahoud, MD, NYU Langone Health
November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

Maggie L. Shaw
In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
AJMC
November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH
Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
doc reviewing lung report | Image Credit: © meeboonstudio - stock.adobe.com
November 8th 2024

Research Reveals Common Types of Rituximab-Induced Interstitial Lung Disease in Patients With Lymphoma

Karen Jacobson-Sive
Rituximab-induced interstitial lung disease in patients with non-Hodgkin lymphoma presents with distinct clinical characteristics and bronchoalveolar lavage results.
Karen Winkfield, MD, PhD
November 7th 2024

Adapting Cancer Treatment for Survivorship and Precision Care

Maggie L. Shaw
The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”
Fish oil supplements in fish shape | Image credit: zilvergolf – stock.adobe.com
November 5th 2024

High Omega-3, Omega-6 Levels May Lower Cancer Risk

Hayden E. Klein
Higher levels of these fatty acids may reduce the risk of developing several types of cancer, though certain risks, such as a potential link to prostate cancer, highlight the complexity of their impact on overall cancer risk.
Cancer disparities | Image credit: Yurii Kibalnik - stock.adobe.com
November 4th 2024

Disparities in Cancer Mortality Among Asian Americans and Pacific Islanders

Pearl Steinzor
Despite an overall decline in cancer-specific mortality, death rates from certain cancer types are rising among Asian American and Pacific Islander populations.
Smoking | Image credit: ehabeljean - stock.adobe.com.jpg
October 31st 2024

Early Smoking Cessation Treatment After Cancer Diagnosis Improves Survival

Pearl Steinzor
Smoking after a cancer diagnosis increases risk of mortality and a second cancer, study finds.
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
October 28th 2024

Transforming Oncology Care With AI-Driven Insights

Pearl Steinzor
Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.
Vinayak Venkataraman, MD
October 24th 2024

Sarcoma Care: Biomarker Advancements Shape the Future

Maggie L. Shaw
At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Gut health concept | Image credit: faithie - stock.adobe.com
October 23rd 2024

Ixcela, Roper St. Francis Healthcare Launch Innovative Cancer Support Program to Improve Treatment Outcomes

Pearl Steinzor
A pioneering program targeting gut microbiome health significantly reduces cancer treatment side effects, enhancing patient well-being and resilience.
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
October 21st 2024

Bridging the Digital Divide of Rural Cancer Care With Telehealth

Cameron Santoro
Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.
Hari Deshpande, MD, Yale Cancer Center
October 17th 2024

Elevating Sarcoma Outcomes Through Value-Based Care

Maggie L. Shaw
At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.
Advancing health equity can be achieved through community engagement | image credit: Andrii - stock.adobe.com
October 16th 2024

Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity

Kyle Munz
Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Screenshot of an interview with Terry Keys
October 16th 2024

Combatting Misconceptions of Clinical Trials to Improve Patient Participation

Laura Joszt, MA
There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Screenshot of an interview with Naoto Ueno, MD, PhD
October 15th 2024

Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage

Alexandra Gerlach Laura Joszt, MA
Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Medicinal cannabis | image: NJ.gov
October 14th 2024

Navigating the Complexities of Cancer Care: Cannabis and Cost Considerations

Laura Joszt, MA
Doing Things Differently: Wilfong Moves to Thyme Care
October 12th 2024

Doing Things Differently: Wilfong Moves to Thyme Care

Mary Caffrey
Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.
Oncology models | Image credit: Navista
October 11th 2024

Tangle of Tech: How Community Oncology Practices Can Successfully Navigate the Health Technology Landscape

Nini Wu, MD, MBA Anish Arora
Patient Navigation | Image credit: CDC
October 11th 2024

Setting the Course for Comprehensive Care Navigation in Oncology

Vishnukamal Golla, MD, MPH Allan Zuckoff, PhD Lucy MacPhail, PhD John Tam, MD Chevon Rariy, MD
AJMC
October 11th 2024

Racial and Ethnic Disparities in Prior Authorizations for Patients With Cancer

Benjamin Ukert, PhD Stephanie Schauder, PhD Daniel Cullen, PhD David Debono, MD Michael Eleff, MD Michael J. Fisch, MD, MPH
The prior authorization process for patients with cancer demonstrates fewer days until submission and lower denial rates for Asian patients relative to White patients.
Corey McEwen, PharmD, MS
October 10th 2024

Defining Value in Oncology Pharmacy: Insights on Care and Costs

Maggie L. Shaw
The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.
Hands holding green lymphoma ribbon | Image credit: sulit.photos - stock.adobe.com
October 9th 2024

Childhood Lymphoma: Raising Awareness for Early Detection and Better Outcomes

Pearl Steinzor
It is important to educate and bring awareness to childhood lymphoma, its symptoms, treatment options, and the need for support.
Cancer screening | Image credit: kenchiro168 - stock.adobe.com
October 3rd 2024

Fear of Recurrence Is Common Among Adult Survivors of Childhood Cancer

Pearl Steinzor
Adults who survived childhood cancer experience elevated fear that their primary cancer will recur or that a subsequent malignant neoplasm will develop, according to a new study.
Managing AEs of Cannabis Use in Patients With Cancer
September 29th 2024

Managing AEs of Cannabis Use in Patients With Cancer

Laura Joszt, MA
There are some short-lived, common adverse events for patients using cannabis, but also some more dangerous, less common ones in chronic users, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
dr linda bosserman
September 27th 2024

Expanding Access to Innovative Cancer Treatments

Brooke McCormick
Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, discusses the implementation of cutting-edge cancer treatments, emphasizing the need for effective information sharing and collaboration to improve cancer care access for diverse populations.
dr andrew leitner
September 26th 2024

Increasing Access to Supportive Oncology Care Can Drive Health Equity

Brooke McCormick
Andrew Leitner, MD, of City of Hope, discusses the challenges of integrating supportive care into cancer treatment and proposes solutions to improve access for patients from underserved communities.
<12345678910
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo